Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors. Learn about the latest clinical data for Signatera and explore how this unique ctDNA assay can be applied in pharmaceutical development and oncology clinical study design, potentially increasing the probability of trial success, reduce the time to trial readout, and decrease clinical trial costs.
Topics will include:
- Advantages of a custom-designed assay for longitudinal monitoring of ctDNA
- Signatera clinical data in colorectal, breast, non-small cell lung, and muscle-invasive bladder cancers
- Applications of Signatera in clinical trial design to maximize trial success, reduce time to data readout, and decrease costs